GSK beat Q3 2026 earnings estimates as specialty medicine sales grew

GSK shares fell 5.5% despite better-than-expected earnings, due to weaker vaccine sales, restructuring costs, and a cautious outlook. The company reported a 19% decline in pre-tax profit to £1.9bn and £318m in restructuring charges. Sales rose 5% to £8.9bn, driven by HIV, cancer, and lupus drugs, but vaccine sales dipped 2%. GSK aims to generate £40bn in annual revenue by 2031 and is implementing a cost-saving plan to save £1.9bn annually.

GSK's shares fell 7% as vaccine sales declined 2% to £2.6B, despite a 5% rise in core operating profits to £3.08B. Shingrix and Arexvy sales dropped 5% and 24%, respectively. Speciality medicines and cancer treatments saw gains. CEO Luke Miels faces pressure to develop new treatments ahead of patent expirations.

GSK reported Q3 sales and profit beats, driven by specialty medicines, but shares fell 5.4% as investors questioned growth plans. Revenue rose 5% to £8.89B, beating expectations. GSK aims to generate £40B in annual revenue by 2031 and maintain 2026 growth forecasts. Core profit was 54.6p per share, above estimates.

The FTSE 100 fell 0.29% to 10,655.85 at noon on Wednesday. GSK shares dropped 6% despite beating Q3 sales and profit expectations, reporting a profit before tax of £1.935B, down from £2.456B a year ago. The company maintained its 2026 guidance.

GSK shares fell 5% despite £8.9bn Q3 revenue, up 5% YoY, as vaccine sales declined 2% to £2.6bn. Speciality medicines drove growth. Analysts remain divided on outlook. CEO Luke Miels highlighted strong quarterly performance and R&D focus.

GSK reported a 23% drop in Q3 profit to £1.5B due to restructuring costs, but reaffirmed full-year guidance. Revenue rose 4% to £8.9B, driven by cancer, respiratory, and HIV drugs. The company aims for £1.9B in annual savings by 2029. Shares fell 5% in early trading.